SELLAS Life Sciences Group, Inc. (NasdaqCM: SLS)
Health Care · Biotechnology · US
$14.33
-7.34% today · +650.0% 1Y
SELLAS Life Sciences Group, Inc. (NasdaqCM: SLS) operates in the Biotechnology industry within the Health Care sector. The company is valued at $2.89B and employs 13 people.
Over the last twelve months the share price has gained 650.0%, trading between 1.39 and 15.88.
Tweenvest scores SELLAS Life Sciences Group, Inc. across four factors: quality 26/100. Its strongest factor is quality.
SLS price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $2.89B
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.21
- Dividend yield
- —
- Beta (5Y)
- 2.49
- 52-week high
- $15.88
- 52-week low
- $1.39
- Avg volume (3M)
- —
- Shares outstanding
- 201.95M
- Employees
- 13
- Next earnings
- —
About SELLAS Life Sciences Group, Inc.
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
- ISIN
- US81642T2096
- Listed since
- Mar 12, 2008
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $264.52 | -0.17% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $443.84 | +1.03% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $146.74 | +0.42% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $547.59 | -0.08% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $828.50 | -0.66% |
| argenx SEENXTBR: ARGX | $63.06B | €864.20 | -4.19% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $138.89 | -4.26% |
Figures last refreshed Aug 18, 2026.